Professor Gianfilippo Bertelli : General (internal) medicine , Medical oncology

Home
Professor Gianfilippo Bertelli

Bupa Platinum consultant
Fee assured
Awaiting verification
Open Referral network

Overview

Offers

Face-to-face consultations
Video and telephone consultations
Home chemotherapy

About me

I am a Consultant Medical Oncologist at the Sussex Cancer Centre in Brighton, and Honorary Clinical Professor at the Brighton and Sussex Medical School. I trained in Genoa, Italy, where I qualified as MD in 1986. I started my career at Genoa’s National Cancer Institute, and also worked at the Santa Croce Hospital in Cuneo (Piedmont). In 2002 I moved to Swansea, UK, where I worked as a Consultant and Honorary Senior Lecturer until February 2018. I have served as Research Lead for the South West Wales Cancer Centre and as a member of the NCRI Breast Cancer Studies Group.
My main clinical and research interests are treatments of early and advanced breast cancer with chemotherapy, hormone therapy and targeted agents. I have contributed to several national and international clinical trials as Principal Investigator, Chief Investigator or Steering Committee Member. I am the Author or co-Author of more than 100 publications and in 2007 I was awarded a PhD from the University of Maastricht for research in the field of endocrine treatment of breast cancer.

Areas of interest

Breast cancer; chemotherapy; hormone therapy; targeted treatments

Medical secretaries

Louise Ray
Nuffield Health Brighton Hospital Warren Road Brighton BN2 6DX
01273 627054
louiseraysecretary@gmail.com

About me

Current NHS consultant posts held

Consultant Medical Oncologist, Brighton and Sussex University Hospitals NHS Trust, Brighton.
Honorary Clinical Professor, Brighton and Sussex Medical School.

Research interests

Principal Investigator in multicentre clinical trials for breast cancer. Member of the National cancer Research Institute Advanced Breast Cancer Trials subgroup.

Personal interests

Walking, cycling, classic music and literature.

(Additional) Languages spoken

Publications

Hall M, Bertelli G, Li L et al. Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. International Journal of Gynecological Oncology 2020:30:213-220

Raouf S, Bertelli G, Ograbek A, Field P, Tran I. Real-world use of bevacizumab
in metastatic colorectal, metastatic breast, advanced ovarian and cervical
cancer: a systematic literature review.
Future Oncology 2019;15:543-561.

Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L.
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data.
Journal of Clinical Oncology 2018;36:1981-1990

Brown J, Rathbone E, Hinsley S, Gregory W, Gossiel F, Marshall H, Burkinshaw R, Shulver H, Thandar H, Bertelli G, Maccon K, Bowman A, Hanby A, Bell R, Cameron D, Coleman R.
Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
Journal of the National Cancer Institute 2018;110:871-879

Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM; TACT2 Investigators.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncology 2017;18:929-945

Leonard R, Adamson D, Bertelli G, et al.
GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
Annals of Oncology 2017;28;1811-1816

Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, LÃ¸nning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM,Coombes RC.
Long-Term Follow-Up of the Intergroup Exemestane Study.
Journal of Clinical Oncology 2017;35:2507-2514

My qualifications & training

Qualifications

MD University of Genoa, Italy 1986
PhD University of Maastricht, The Netherlands 2007
FRCP (Edin) Royal College of Physicians, Edinburgh 2003

GMC registration

Reference number 6057041

Details of entry to specialist register

Medical Oncology , 2003

Affiliations / memberships

ASCO (American Society of Clinical Oncology)
ESMO (European Society of Medical Oncology)
ACP (Association of Cancer Physicians)
ACCOG (Anglo-Celtic Co-operative Oncology Group)
UKBCG (UK Breast Cancer Group)

My private practice

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

X0001
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 0-7 days - (5-50)

Nuffield Health Brighton Hospital (1-5)
X0003
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (5-50)
X0002
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-14 days - (1-5)
X0004
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (1-5)

Report this page Print page

Finder

Note: